Centrus Energy Corp. (LEU) | The Buildout — AI Infrastructure

Mkt cap · 52-wk · YTD · delayed
Updated Aug 12, 2026Q1 FY2026 reviewed
Centrus Energy Corp. supplies low-enriched uranium and HALEU nuclear fuel for reactors powering AI infrastructure.
Backlog $4.5B
Up from $3.9B in Q1; extends through 2040.
75% critical suppliers
Contracts with about three-quarters of critical suppliers finalized in Q2.
2 HALEU offtakes
X-energy definitive agreement; Oklo letter of intent.
SWU volume -23%
Q2 SWU volume fell 23% y/y, partially offset by 3% price.
The Buildout Takeaway
Centrus is converting a government-supported HALEU demonstration into a commercial domestic enrichment build-out. The open question is whether first-of-a-kind centrifuge manufacturing and early-stage offtakers can turn a long-dated order book into delivered revenue on schedule.
12 analysts·5 Buy7 Hold0 Sell
Median target$246  Range $170–$300 · 7 estimates

$450M–$500M FY2026 revenue · $350M–$500M capital spend · over 175 net new Piketon employees
Important: The Buildout is a data analytics platform. Content is generated by algorithms and AI agents using public filings, earnings transcripts, and market data. This is not personalized investment advice.
Our View

The Verdict

Centrus Energy Corp. supplies nuclear fuel components and enrichment services. It operates a low-enriched uranium segment serving commercial utilities and a technical solutions segment that produces HALEU for advanced reactors and government customers. In the AI buildout, it is not a compute or data-center company; its role is the fuel behind the nuclear reactors tied to AI-driven electricity demand. The company is building domestic centrifuge manufacturing and enrichment capacity to move from a government demonstration program toward commercial supply.

Market Cap
Revenue (TTM)$452M
Revenue Growth−4.1%
EBITDA Margin (TTM)9.1%
Net Cash$690M
Earnings Beats4 of 7
P/E (TTM)
EV/EBITDA (TTM)

What We Like

  • Total backlog reached $4.5 billion and extends through 2040, including $3.0 billion of LEU/HALEU enrichment sales within the LEU segment.
  • All financial contingencies were removed on more than $3 billion of customer contracts; $2.4 billion of the enrichment backlog is under definitive agreements.
  • The $900 million DOE HALEU enrichment contract was signed July 1, 2026, with DOE options up to $170 million.
  • X-energy signed a definitive LEU and HALEU supply agreement, and Oklo has an HALEU LOI covering up to 5 Aurora powerhouses with deliveries from 2029.
  • Critical supplier contracts increased from about one-third in Q1 to about 75% in Q2, and Piketon hiring guidance was raised to over 175 net new employees.

What We’re Watching

  • First centrifuge completion is targeted for 2026 but not yet complete; first new Piketon enrichment capacity is targeted for 2029.
  • Through 2027, well over half of expected LEU deliveries are sourced under the TENEX Supply Contract, and the 10-K says other sources are not sufficient to replace it.
  • Customer concentration is high: the top four customers represented 16%, 15%, 13%, and 11% of FY2025 revenue, and one Q1 Technical Solutions customer was $31.5 million of $32.1 million segment revenue.
  • The new HALEU offtakers are early-stage: Oklo is still at LOI stage, and X-energy delivery cadence and terms were not disclosed.
Bottom Line

The commercial-order evidence is strengthening: backlog grew, contingencies were removed, the DOE contract was signed, and first HALEU offtake agreements arrived. The thesis remains intact directionally, but near-term revenue is still broker, uranium, and government-led, and the core manufacturing proof is pending. The key open question is whether first-of-a-kind centrifuge production can reach the 2029 capacity target on time and on cost while TENEX dependence persists through 2027.

Next upThe next visible test is first centrifuge completion at Oak Ridge, promised sometime in 2026; it tests whether the manufacturing supply chain has actually come together. After that, the first certified-for-construction package and 100% critical supplier contracts are also targeted for FY2026.
Last Quarter — Q1 FY2026

Earnings Beat

Centrus reported Q2 2026 revenue of $176.1 million, up 14% year over year, with gross profit of $49.9 million. GAAP net income was $16.8 million, down from $28.9 million a year earlier, while adjusted net income was $38.7 million. The standout was the backlog: $4.5 billion, with all financial contingencies removed from the $3.0 billion LEU/HALEU enrichment backlog.

MetricQ1 FY2026Q4 FY2025Q1 FY2025YoY
Revenue$77M$146M$73M+4.9%
Gross margin38.7%23.9%45.0%-630bps
EBITDA$3M$16M$22M−86.4%
EPS$0.45$0.79$1.60−72.1%
Total backlog$4.5B$3.9Bn/a
We grew our backlog to $4.5 billion that extends through 2040. This is comprised of $3.7 billion in our LEU segment and $0.8 billion in our Technical Solutions segment.— Amir Vexler, CEO, Q2 2026 call

Management tone: Management's tone became more declarative from Q1 to Q2. It moved from describing the build-out as 'historic' and deconversion as 'exploring' to stating Centrus is 'leading the pack' and 'the go-to for HALEU supplies.'

Management Guidance

Management reaffirmed FY2026 revenue guidance of $450 million to $500 million and total capital spend of $350 million to $500 million. Piketon workforce additions were raised from over 100 to over 175 net new employees, while Oak Ridge remains at least 100. The company still targets 100% of critical partner contracts finalized and release of the first certified-for-construction package in FY2026.

Business Trajectory

Trajectory

Revenue is lumpy rather than linear: Q1 2026 was $76.7 million, up 5% year over year, and Q2 2026 was $176.1 million, up 14% year over year, with the Q2 increase carried by $53.4 million of uranium sales. SWU volume fell 47% in Q1 and 23% in Q2, while average SWU price rose 52% and 3%. Reported gross margin was 38.7% in Q1 and 28.3% in Q2, reflecting a mix shift toward lower-margin uranium sales; management points to TTM and adjusted figures because quarterly revenue is not a reliable trend signal.

Revenue & Margin Trajectory
RevenueGross margin$0$100$63M$21M$136M$7M$44M$50M$117M$36M$39M$34M$84M$39M$11M$105M$56M$45M$76M$34M$93M$56M$62M$91M$89M$35M$99M$33M$126M$67M$98M$51M$104M$44M$189M$58M$152M$73M$154M$75M$146M$77M9%39%crosses into profitQ2'16Q3Q4Q1'17Q2Q3Q4Q1'18Q2Q3Q4Q1'19Q2Q3Q4Q1'20Q2Q3Q4Q1'21Q2Q3Q4Q1'22Q2Q3Q4Q1'23Q2Q3Q4Q1'24Q2Q3Q4Q1'25Q2Q3Q4Q1'26
RevenueGross margin$0$100$63M$21M$136M$7M$44M$50M$117M$36M$39M$34M$84M$39M$11M$105M$56M$45M$76M$34M$93M$56M$62M$91M$89M$35M$99M$33M$126M$67M$98M$51M$104M$44M$189M$58M$152M$73M$154M$75M$146M$77M9%39%crosses into profitQ2'16Q3Q4Q1'17Q2Q3Q4Q1'18Q2Q3Q4Q1'19Q2Q3Q4Q1'20Q2Q3Q4Q1'21Q2Q3Q4Q1'22Q2Q3Q4Q1'23Q2Q3Q4Q1'24Q2Q3Q4Q1'25Q2Q3Q4Q1'26
Gross margin as reported.
Share Price — 12 Months
$200$400$052-wk high $436Aug '25NovFeb '26MayAug '26
52-week range $156–$436.
Share Price — 12 Months
$200$400$052-wk high $436Aug '25NovFeb '26MayAug '26
52-week range $156–$436.
The Numbers

The Model

The model projects FY+1 revenue of $490 million and EBITDA of $81 million, a 16.6% margin, and FY+2 revenue of $660 million and EBITDA of $104 million, a 15.8% margin. The FY+1 revenue sits within management's current-year guidance band of $450 million to $500 million; the FY+2 step-up depends on continued conversion of the long-dated order book and build-out execution.

Revenue & EBITDA Projections
REVENUE$449M$490M$660MFY25FY+1 (E)FY+2 (E)EBITDA & MARGIN$60M$81M$104M15.8%FY25FY+1 (E)FY+2 (E)
REVENUE$449M$490M$660MFY25FY+1 (E)FY+2 (E)EBITDA & MARGIN$60M$81M$104M15.8%FY25FY+1 (E)FY+2 (E)
Solid bars are reported actuals; outlined bars are model projections — not company guidance.
MetricFY2025Next FY (E)Following FY (E)
Revenue$449M$490M$660M
YoY Growth+9.2%+34.7%
EBITDA$60M$81M$104M
EBITDA Margin13.4%16.6%15.8%

Projections are the median of 5 independent model runs. The model’s revenue sits 33.5% above analyst consensus.

Management reaffirmed FY2026 revenue guidance of $450 million to $500 million and total capital spend of $350 million to $500 million. Piketon workforce additions were raised from over 100 to over 175 net new employees, while Oak Ridge remains at least 100. The company still targets 100% of critical partner contracts finalized and release of the first certified-for-construction package in FY2026.

What Could Go Right — and Wrong

What good looks like
  • First Oak Ridge centrifuge is completed in 2026 and the certified-for-construction package is released, proving the manufacturing supply chain.
  • The existing 16-centrifuge HALEU cascade transitions to private commercial operation before the 2029 capacity arrives.
  • Oklo converts its LOI into a definitive HALEU agreement, and X-energy delivery cadence becomes visible.
  • More utility LEU offtake follows the removal of financing contingencies, expanding the $3.0 billion enrichment backlog.
  • NNSA awards a material sole-source enrichment contract, adding another government-funded leg.
What could go wrong
  • TENEX supply is disrupted through 2027, and alternative suppliers cannot replace it.
  • First centrifuge completion slips past 2026 or the 2029 first-capacity target slips.
  • X-energy or Oklo stumble before definitive delivery obligations bind.
  • DOE discussions stall on private commercial operation of the existing cascade.
  • SWU volume weakness continues, as seen in the 47% Q1 and 23% Q2 declines.
What’s Next

Looking Ahead

The next twelve months are defined by manufacturing-readiness milestones rather than new capacity revenue. Management expects the first Oak Ridge centrifuge in 2026, the first certified-for-construction package in FY2026, and 100% of critical supplier contracts by year-end. Into early 2027, the IRS $62.4 million credit allocation certification is due on January 10, 2027.

Catalysts
  • 2026First Oak Ridge centrifuge completion — Tests whether the domestic manufacturing supply chain has come together.
  • FY2026First certified-for-construction package — Engineering readiness marker for new enrichment capacity.
  • FY2026100% critical supplier contracts — Reached about 75% by Q2; target is full coverage.
  • FY2026Piketon 175+ net hires — Workforce expansion target raised twice during 2026.
  • 2029First new Piketon capacity — First new capacity from the transition expected online by 2029.
  • January 10, 2027IRS credit allocation certification due — Evidence due for the $62.4 million credit allocation.
Numbers

Financials

Annual Summary

MetricFY2024FY2025TTMYoY
Revenue$442M$449M$452M+1.5%
Gross Margin20.2%24.5%25.3%+430bps
EBITDA$59M$60M$240M+2.2%
EBITDA Margin13.3%13.4%9.1%+9bps
Net Income$73M$78M$61M+6.3%
Free Cash Flow$33M$31M$134M
Net Cash

Key Ratios (Trailing)

Valuation
  • P/E TTM
  • EV/EBITDA TTM
  • EV/Revenue TTM
  • Price/FCF TTM
Profitability
  • Gross Margin (TTM)25.3%
  • EBITDA Margin (TTM)9.1%
  • Net Margin (TTM)13.4%
  • ROIC28.1%
  • FCF Conversion-149.4%
  • SBC / Revenue1.3%
Reference

The Company

Centrus Energy Corp. supplies nuclear fuel components and enrichment services across two segments. The LEU segment provides SWU, natural uranium hexafluoride, uranium concentrates, uranium conversion, and enriched uranium product to commercial utilities. The Technical Solutions segment provides HALEU and advanced manufacturing and engineering services, mainly to government and private customers. The company's role is fuel supply for existing reactors and emerging advanced reactors that are increasingly tied to AI-driven electricity demand.

Operations are anchored by three sites: an owned 440,000 square foot centrifuge manufacturing facility on 72 acres in Oak Ridge, Tennessee; a DOE-leased enrichment facility in Piketon, Ohio with an existing 16-centrifuge HALEU cascade; and a leased 24,000 square foot headquarters in Bethesda, Maryland. The company is building out Oak Ridge manufacturing under a $560 million investment and expanding Piketon under a $900 million DOE task order. It uses Fluor as EPC contractor and Palantir as a strategic AI partner to optimize the build-out.

Business Segments

LEU segment
Historically most revenue; $3.7B backlog at Q2 2026
Supplies SWU, natural uranium hexafluoride, uranium concentrates, conversion, and enriched uranium product to utilities.
Growth driver: Long-term LEU pricing ascent and SWU seller's market.
Technical Solutions segment
$0.8B backlog at Q2 2026
Provides HALEU and advanced manufacturing / engineering services to government and private customers.
Growth driver: HALEU demand from advanced reactors and DOE awards.

Competitive Landscape

Centrus management describes the company as the only company with a proven American technology that can meet commercial LEU, HALEU, and national security demand; this is a management claim. The 10-K names Rosatom/TENEX, Urenco, CNEIC, and Orano as competitors. Management also frames the SWU market as a seller's market, with demand outstripping supply.

  • Rosatom / TENEX
    Russian government entity; sells LEU through TENEX. Named in 10-K.
  • Urenco
    Consortium owned/controlled by British and Dutch governments and two German utilities. Named in 10-K.
  • CNEIC
    Chinese government-owned. Named in 10-K.
  • Orano
    Largely French government-owned; also Centrus's second-largest SWU supplier.
Rosatom/TENEX, Urenco, CNEIC, and Orano are from the 10-K.

Supply Chain

Centrus sits between enriched uranium suppliers and nuclear utilities and advanced reactor developers while building domestic centrifuge capacity to reduce reliance on imported SWU.

Supplier
TENEX
Largest SWU supplier; SWU contained in LEU
Supplier
Orano
Second-largest SWU supplier
Supplier
Fluor
EPC contractor for enrichment expansion
Supplier
Geiger Brothers
On-the-ground construction in Ohio
Supplier
Palantir
Foundry/AI platform for build-out optimization
management-cited proven American enrichment technology
LEU
Brokers and supplies LEU today while building domestic HALEU and LEU enrichment capacity.
U.S. DOE
HALEU operations and $900 million HALEU enrichment award
NNSA
Sole-source enrichment activities in procurement
X-energy
Definitive LEU and HALEU supply agreement
Up to 5 Aurora powerhouses
HALEU supply letter of intent
Customers A–D (unidentified)
55% of FY2025 revenue
16%, 15%, 13%, 11% of revenue

Analysis updated Aug 12, 2026, reviewing Q1 FY2026. Prices delayed. Built with The Buildout’s published methodology. Not investment advice. No positions held. © The Buildout 2026.

More on LEU: Earnings recap